Search clinical trials for: Positive for FLT3-ITD Mutation

Total 366048 results

AstraZeneca

Completed

Phase I, Study in Chinese NSCLC Patients (AURAChinaPK)

Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive

China
M.D. Anderson Cancer Center
Bayer

Completed

Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

Leukemia

United States
Hoffmann-La Roche

Completed

An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma

Malignant Melanoma

South Africa
Allist Pharmaceuticals, Inc.

Unknown

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer

China
Daiichi Sankyo, Inc.
Ambit Biosciences Corporation

Completed

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

United States, France, Italy, United Kingdom
AstraZeneca
Medpace, Inc.

Completed

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients (RADIANCE)

Non-small Cell Lung Cancer

United States, Canada
Nanfang Hospital of Southern Medical University
Xiangya Hospital of Central South University; Peking University People's Hospital and other collaborators

Completed

Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML

Acute Myeloid Leukemia | Hematopoietic Stem Cell Transplantation

China
Hoffmann-La Roche

Completed

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

Malignant Melanoma

United States, Australia
National Cancer Institute (NCI)
NRG Oncology

Completed

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Ovarian Epithelial Tumor

United States
Peking Union Medical College

Unknown

Clinical Value of Next Generation Sequencing in Endocrine Therapy for Advanced Hormone Receptor Positive/HER-2 Negative Breast Cancer

Breast Neoplasm Female | Mutation | Therapeutics

China
Hoffmann-La Roche

Completed

A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Malignant Melanoma

China
Novartis Pharmaceuticals

Completed

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Melanoma and Brain Metastases

Canada, United States, Australia, France, Germany, Italy, Spain
MedImmune LLC

Completed

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Melanoma

Italy, United States, Canada, France
University of Chicago
Novartis

Terminated

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma | Human Papillomavirus Infection | Recurrent Oropharyngeal Squamous Cell Carcinoma | FGFR Gene Amplification | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | Recurrent Nasopharynx...

United States
Novartis Pharmaceuticals

Completed

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

Cancer

United States, Canada, Australia, France, Germany, Poland, Spain, United Kingdom, Italy
Mediclinic Middle East

Unknown

Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation (Pembro)

Breast Cancer Female

United Arab Emirates
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Non-Small-Cell Lung Cancer

Japan
Hoffmann-La Roche

Completed

A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU]) (MELANIS)

Melanoma

France
Placon Therapeutics

Unknown

A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

Breast Neoplasms | Prostatic Neoplasms | Pancreatic Neoplasms | Ovarian Neoplasms

United States
University of Miami
Massachusetts General Hospital

Completed

Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States
Fudan University
Betta Pharmaceuticals Co., Ltd.

Unknown

X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Nonsmall Cell Lung Cancer | Brain Metastases
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Novartis Pharmaceuticals

Withdrawn

Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

Non-Small-Cell Lung Cancer
Cancer Trials Ireland

Completed

Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia

United States, Ireland, Israel, Germany
AstraZeneca

Completed

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

Non Small Cell Lung Cancer

United States, Belgium, France, Italy, Spain, Canada, Brazil, Hungary, Peru, Czechia, Bulgaria, Mexico
Hoffmann-La Roche

Completed

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

Malignant Melanoma

Italy, United Kingdom, Belgium, Poland, Netherlands, Germany, Austria, Czechia, Ireland, Sweden
National Cancer Institute (NCI)

Completed

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast... and other conditions

United States
GlaxoSmithKline

Completed

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Melanoma

United States, Italy, United Kingdom, France, Sweden, Germany, Poland, Australia, Belgium, Austria, Canada, Czechia, Greece, Russian Federation, Ukraine, Norway, Switzerland, New Zealand, Argentina
Hoffmann-La Roche

Completed

A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants

Neoplasms

United Kingdom, Israel, United States, Russian Federation, Australia, Greece, Turkey
University College, London
National Institute for Health Research, United Kingdom

Completed

Improving the Management of Drug Resistant Tuberculosis in the UK (UK_DR-TB)

Tuberculosis

United Kingdom
GlaxoSmithKline

Withdrawn

Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

Cancer | Metastatic Uveal Melanoma | GNA11 Mutation-positive Metastatic Melanoma | GNAQ Mutation-positive Metastatic Melanoma
Hoffmann-La Roche

Completed

A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

Multiple Myeloma, Neoplasms

United States, China, France, Spain, United Kingdom, Germany
GlaxoSmithKline

Completed

A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

Cancer

Australia, United States, United Kingdom
GlaxoSmithKline

Completed

An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor

Cancer

United States
Hoffmann-La Roche

Completed

Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies

Malignant Melanoma, Cancer

Hungary
GlaxoSmithKline

Completed

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Solid Tumours

United States
GlaxoSmithKline

Completed

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors

Cancer

Japan
GlaxoSmithKline

Completed

Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Cancer

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

Cancer

United States, Australia, United Kingdom
GlaxoSmithKline

Completed

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Cancer

Australia, Spain, United States, Germany, Poland, Italy, Canada, Ireland, Hungary, Russian Federation, Netherlands, France
GlaxoSmithKline

No longer available

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

Melanoma

France
European Organisation for Research and Treatment...

Unknown

Study of Blood and Tissue Samples in Children With Newly Diagnosed Acute Lymphoblastic Leukemia

Lymphoma | Leukemia

France, Belgium, Portugal
GlaxoSmithKline

Completed

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Solid Tumours

Japan
National Cancer Institute (NCI)

Completed

Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas

Solid Tumors | Lymphomas

United States
Hoffmann-La Roche

Completed

A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies

Malignant Melanoma, Neoplasms

Korea, Republic of, Brazil, United States, Canada, Cyprus
Instituto Nacional de Cancerologia de Mexico

Unknown

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

EGFR Gene Mutation | Tyrosine Kinase Mutation | Non-Small Cell Adenocarcinoma

Mexico
Novartis Pharmaceuticals

Completed

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Chronic Myelomonocytic Leukemia | Hypereosinophilic Syndrome | Systemic Mastocytosis | Dermatofibrosarcoma

Australia
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Ponatinib for Advanced Medullary Thyroid Cancer

Thyroid Neoplasms

United States
Singapore General Hospital

Completed

Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy

Chronic Myeloid Leukemia

Singapore
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China

3

Subscribe